Profitable, Scalable, significant upside potential. This business is a leading provider of contract research services and is regarded as an expert in the field of biomarker analysis. They provide a wide range of testing including clinical biomarkers, nucleic acid-based assays, intracellular signalling assays and point-of-care tests. They also provide a range of scientific kits and serum products for clients to undertake their own tests.
Fully Equipped and furnished Lab Significant pipeline of committed work Clients include Universities, CROs, Hospitals and Supplement Industry. Lab to be NATA accredited enabling diversification into Pharma Clinical Trials $378,000/annum Future Maintainable Earnings (Avg. 2022 + 2023) Assets with an estimated value of $750,000 included in the purchase price NATA accreditation (National Association of Testing Authorities) is currently underway and once completed will open a whole new market, including the lucrative pharmaceutical research industry. This is an exciting opportunity for a buyer with ambition and resources to scale this business to its full potential. If you or your organisation have experience managing growth, this opportunity should be investigated.
The current owner would ideally like to keep a stake in the business and participate in its future growth, subject to the skills, reputation and resources of the buyer. Purchase Price $1,500,000 (includes an estimated $750,000 assets) Plus stock at value
A detailed information memorandum is available to qualified parties, copy and paste this link to complete the confidentiality agreement - https://forms.gle/69qVEPYg5KsB3UVKA
Israel 
